louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01254396: Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.
Official title: An Open Label Crossover Study In Healthy Older Male Subjects To Evaluate The Pharmacokinetics And Safety Of An Orally Disintegrating Tablet Formulation Of Sildenafil Administered Without Water Under Fed Compared To Fasted Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Erectile Dysfunction
Keywords: Bioavailability Food Effect Oral Dissolving Tablet (ODT)
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2010-12-06
Enrollment: 12
Sex: MALE
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study will evaluate if an orally disintegrating tablet of sildenafil will have similar pharmacokinetic properties when given with food and without food.


Eligibility criteria: Inclusion Criteria:

* Otherwise healthy male subjects age 45 years or older with or without erectile dysfunction.
* Body Mass Index (BMI) of 17.5 to 32.5 kg/m2.
* Signed Informed Consent.

Exclusion Criteria:

* Evidence or history of clinically significant abnormalities
* Have baseline orthostatic hypotension
* Positive drug screen, excessive alcohol and tobacco use

Primary outcomes:
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
measure: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hours (hrs) post-dose
Secondary outcomes:
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
measure: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
measure: Plasma Decay Half Life (t1/2)
timeFrame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
citation: Damle B, Duczynski G, Jeffers BW, Crownover P, Coupe A, LaBadie RR. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. Clin Ther. 2014 Feb 1;36(2):236-44. doi: 10.1016/j.clinthera.2013.12.010. Epub 2014 Jan 18.
Clinical trial NCT01792596: Satiety Effects of Protein and Fiber Added to Pasta
Official title: Satiety Effects of Protein and Fiber Added to Pasta
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food Selection
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2013-02-15
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The combination of fiber and protein added to pasta will enhance satiety.

Detailed description: Subjects will consume 3 different pasta lunches and satiety will be measured by visual analogue scales. They will consume an ad lib snack after 3 hours and food intake will be measured.

Eligibility criteria: Inclusion Criteria:

* healthy
* nonsmoking
* body mass index from 19 - 29

Exclusion Criteria:

* Antibiotic use
* any disease
* weight loss
* food allergies
* high fiber intake
* restrained eater

Primary outcomes:
measure: satiety
timeFrame: 180 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: St. Paul
country: United States
facility: Department of Food Science and Nutrition
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Joanne Slavin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03121196: Social Deprivation and Pregnancy
Official title: Social Deprivation and Pregnancy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gestational Diabetes
High Blood Pressure
Prematurity
Fetal Growth Restriction
Keywords: Social deprivation
Adverse perinatal outcomes
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2017-04-20
Enrollment: 615
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: pregnant women

Brief summary: Social deprivation during pregnancy is associated to adverse perinatal outcomes. However, prenatal screening of social deprivation by reliable measurement is not performed. Prevalence of social deprivation is yet underestimated during pregnancy and vulnerable women are not being provided optimal prenatal care.

Our aim is to validate EPICES score during pregnancy.

Detailed description: The process of deprivation was defined first by J. Wrezinski and P. Townsend who also reported that deprivation is the main cause of inequalities in health. Several studies have already shown an association between socioeconomic deprivation and adverse birth outcomes. EPICES score is the only one that measure individual deprivation. The EPICES score should be therefore included systematically in standard follow-up of pregnant women.

Descriptive analysis will assess women's characteristics and prevalence of social deprivation. Two groups of women will be compared deprived women and non-deprived women.

Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression.

Eligibility criteria: Inclusion Criteria:

* more than 18 years old
* delivery at 2 maternity hospitals of Clermont-Ferrand area
* fluent command of spoken and written French

Exclusion Criteria:

* Terminations of pregnancy
* protected women

Primary outcomes:
measure: Epices score distribution
timeFrame: at day 1
Secondary outcomes:
measure: Adverse perinatal outcomes
timeFrame: at day 1
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Françoise VENDITELLI
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03216096: Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
Official title: A Prospective, Open Label, One-arm, 4-weeks Study Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease -Phase 1 Study in Dry Eye Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Dry Eye Disease
Lead sponsor: Santen Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2017-07-13
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to assess safety and efficacy of DE-089 ophthalmic solution in patients with dry eye disease in Taiwan.


Eligibility criteria: Inclusion Criteria:

* At least 6-month dry eye history

Exclusion Criteria:

* Diagnosed with Stevens-Johnson Syndrome or ocular pemphigoid
* Diagnosed with keratoconjunctival chemical burns or thermal burn
* Eye disease other than dry eye disease which needs treatment
* Allergic conjunctivitis that may possibly be aggravated during the clinical study and inappropriate for efficacy evaluation
* Those who need to wear contact lenses during the clinical study
* Those who are considered inappropriate for this study by the investigator or subinvestigators

Primary outcomes:
measure: Corneal fluorescein staining score
timeFrame: Week 4
Secondary outcomes:
Other outcomes:
Locations:
city: Keelung
country: Taiwan
facility: Keelung Chang Gung Memorial Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT04486196: Effect of Diode Laser on Post-operative Pain After Endodontic Treatment in Teeth With Apical Periodontitis
Official title: Effect of Root Canal Disinfection With 980 µm Diode Laser on Post-operative Pain After Endodontic Treatment in Teeth With Apical Periodontitis: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Apical Periodontitis
Postoperative Pain
Keywords: diode laser
irrigation
post-operative pain
root canal treatment
visual analog scale
Lead sponsor: Biruni University
Sponsor class: OTHER
First posted: 2020-07-24
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Aim: This study aims to assess the effect of root canal disinfection with a 980 µm diode laser following chemomechanical root canal preparation on the severity of pain after root canal treatment (RCT).

Materials and Methods: In present study, asymptomatic, single-rooted teeth with periapical index (PAI) score 3 or 4 were included. All patients were treated with two visits of root canal treatment including dressing with calcium hydroxide. Patients were randomly divided into two groups (n: 28). 'Control (no laser)': The final irrigation was performed using 5ml 2.5% NaOCI, followed by 5 ml 17% EDTA and 5 ml distilled water. 'Laser Disinfection (LD)': Root canals were irradiated with 980 µm diode laser after final irrigation at both visits. The pain levels were evaluated using visual analog scale (VAS) after 8, 24, 48 hours and 7 days. In addition, analgesic intake and time intervals were recorded by patients. The collected data were statistically analyzed with the Chi-square and Mann-Whitney U test (p\<0.05).


Eligibility criteria: Inclusion Criteria:

* Healthy patients
* Patients that had asymptomatic, single-rooted teeth with PAI score 3 or 4

Exclusion Criteria:

* antibiotic use with in the last month,
* anti-inflammatory analgesic use within the last five days,
* systemic disorder, pregnancy or lactation,
* traumatic occlusion,
* presence of other teeth requiring RCT,
* teeth with root canal fillings,
* calcified canals,
* root resorption,
* periodontal diseases,
* sinus tracts
* severe crown destruction preventing rubber-dam application

Primary outcomes:
measure: Post-operative pain
timeFrame: 7 days
Secondary outcomes:
measure: Analgesic intake
timeFrame: 7 days
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Biruni University
Study officials:
affiliation: Biruni University
name: Sema Sönmez Kaplan, DDS, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kaplan T, Sezgin GP, Sonmez Kaplan S. Effect of a 980-nm diode laser on post-operative pain after endodontic treatment in teeth with apical periodontitis: a randomized clinical trial. BMC Oral Health. 2021 Jan 22;21(1):41. doi: 10.1186/s12903-021-01401-w.
Clinical trial NCT02339246: Pharmacokinetic Comparison Of All FK-506 Formulations
Official title: A Steady-state Pharmacokinetic Comparison Of All FK-506 Formulations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Renal Failure
Lead sponsor: Veloxis Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2015-01-15
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the study is to compare the pharmacokinetic parameters of three different formulations of tacrolimus.

Eligible patients will be treated with all three formulations in a pre-defined sequence.

Detailed description: The pharmacokinetic parameters T(max), C(max) and AUC(0-24) will be compared between the three formulations Envarsus XR once daily, Astagraf XL once daily and Prograf Twice daily.

Eligibility criteria: Inclusion Criteria:

1. Renal transplant recipients, males or females, of 18 years of age or above.
2. Able to participate and willing to give written informed consent and to comply with study visits and restrictions.
3. Able to understand English.
4. Patients having received a primary or secondary renal transplant

Exclusion Criteria:

1. Evidence of acute rejection episode within the past three months prior to screening.
2. Recipients of organ transplants other than kidney.
3. Patients who are known to be HIV positive.

Primary outcomes:
measure: Evaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf.
timeFrame: 8 days
measure: Evaluation of C(Max) for Envarsus XR, Astagraf XL and Prograf.
timeFrame: 8 days
measure: Evaluation of AUC(0-24) for Envarsus XR, Astagraf XL and Prograf.
timeFrame: 8 days
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: University of Cincinnati
state: Ohio
Study officials:
affiliation: University of Cincinnati
name: Rita Alloway, PharmD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Philosophe B, Leca N, West-Thielke PM, Horwedel T, Culkin-Gemmell C, Kistler K, Stevens DR. Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended-Release Once-Daily Tacrolimus Tablets. J Clin Pharmacol. 2018 Jul;58(7):891-896. doi: 10.1002/jcph.1082. Epub 2018 Feb 20.
citation: Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. Am J Transplant. 2017 Feb;17(2):432-442. doi: 10.1111/ajt.13935. Epub 2016 Aug 2.
Clinical trial NCT04637646: Evaluation of Cardiac Affections in Patients With Mucopolysaccharidosis (MPS) in Assuit University Children Hospital (AUCH)
Official title: Evaluation of Cardiac Affections in Patients With Mucopolysaccharidosis (MPS) in Assuit University Children Hospital (AUCH)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mucopolysaccharidoses
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-11-20
Enrollment: 25
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with mucopolysacchridosis

Brief summary: This study aims to evaluate the different cardiac changes in the various types of MPS disorder and define the outcome of these cardiac abnormalities in those patients admitted to assuit University Children Hospital

Detailed description: The mucopolysaccharidoses (MPSs) are inherited lysosomal storage disorders caused by the absence of functional enzymes that contribute to the degradation of glycosaminoglycans (GAGs). The progressive systemic deposition of GAGs results in multi-organ system dysfunction that varies with the particular GAG deposited and the specific enzyme mutation(s) present.

Cardiac involvement has been reported in all MPS syndromes and is a common and early feature, particularly for those with MPS I, II, and VI. Cardiac valve thickening, dysfunction (more severe for left-sided than for right-sided valves), and hypertrophy are commonly present; conduction abnormalities, coronary artery and other vascular involvement may also occur. Cardiac disease emerges silently and contributes significantly to early mortality. The clinical examination of individuals with MPS is often difficult due to physical and, sometimes, intellectual patient limitations. The absence of precordial murmurs does not exclude the presence of cardiac disease. Echocardiography and electrocardiography are key diagnostic techniques for evaluation of valves, ventricular dimensions and function.

Eligibility criteria: Inclusion Criteria:

- All the patients at any age up to 18 years with any type of MPS confirmed by the enzymatic assay

Exclusion Criteria:

* any patient other than MPS

Primary outcomes:
measure: Rate of Cardiac affection in patients with MPS
timeFrame: on enrollment
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04195646: Computer Aided Detection of Polyps During Colonoscopy Procedures
Official title: Computer Aided Detection of Polyps During Colonoscopy Procedures
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colo-rectal Cancer
Polyp of Colon
Adenomatous Polyps
Lead sponsor: EndoVigilant Inc
Sponsor class: INDUSTRY
First posted: 2019-12-12
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The focus of the study is to evaluate impact on Adenomas Per Colonoscopy (APC) with a Computer Aided Detection (CAD) software assisting the gastroenterologist during a colonoscopy procedure.

Detailed description: The details of the proposed study are as follows:

1. Colonoscopy will be performed in the same standard of care manner as if no study was taking place. The video signal from the colonoscope will be fed into a computer running the EndoVigilant CAD software in addition to the standard video output to the procedure monitor. The EndoVigilant CAD software will display an annotated video on an additional monitor that includes both the colonoscopy picture and annotation by the software indicating the location of any polyps on the screen.
2. The endoscopist performing the procedure will therefore be able to observe a standard colonoscopy video on the primary monitor and the annotated video on the second monitor.
3. The endoscopist will primarily rely on the second monitor (augmented with annotation from EndoVigilant ColonCAD software) but the standard procedure monitor will be always operational and available for maneuvers such as fast insertion, polypectomy etc.

Eligibility criteria: Inclusion Criteria:

* Patient presenting for routine colonoscopy for screening and/or surveillance purposes
* Ability to provide written, informed consent and understand the responsibilities of study participation

Exclusion Criteria:

* Patients with diminished cognitive capacity
* Patients with inflammatory bowel disease, ulcerative colitis or Crohn's colitis
* Patients with incomplete colonoscopies (due to technical difficulties or poor bowel prep)

Primary outcomes:
measure: Adenomas Per Colonoscopy
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: VA Palo Alto Healthcare
state: California
city: Greenbelt
country: United States
facility: Greenbelt Endoscopy Center
state: Maryland
Study officials:
References:
Clinical trial NCT03338946: Evaluation of CIED "Readers" for Disease Management
Official title: Evaluation of Cardiac Implanted Electronic Devices (CIED) "Readers" for Hospital Disease Management
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pacemaker Ddd
ICD
Keywords: Remote monitoring
Lead sponsor: Edward-Elmhurst Health System
Sponsor class: OTHER
First posted: 2017-11-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects being seen in Edward ED, HF clinic or inpatient units being evaluated for HF, TIA/stroke or syncope

Brief summary: The purpose of this study is to evaluate the use of remote interrogation (readers) of CIEDs in evaluation of suspected TIA/stroke patients, HF or those experiencing syncope. This approach has the potential to advance the practice of CIED evaluation by staff without specialized training in cardiac electrophysiology (non-EP staff). We hypothesize that actionable events will be identified with use of CIED readers. These events may include identification of atrial fibrillation in TIA/stroke patients, percentage biventricular pacing in patients with HF or evaluation of arrhythmic events in syncope patients. We believe that non-EP staff will find CIED readers easy or very easy to use and that time from transmission to analysis for non-EP trained staff will be low.

Detailed description: Subjects with CIEDs undergoing evaluation for TIA/stroke, HF or syncope will be reviewed for inclusion/exclusion criteria. CIED interrogation, demographics and time of interrogation will be collected. Review of interrogation and medical record will be done to evaluate for actionable events including CIED programming, initiation or change in medications, admission/discharge or decision for further testing.

Eligibility criteria: Inclusion Criteria:

* have a Medtronic CIED compatible with Medtronic CareLink Express
* being evaluated for heart failure, TIA/stroke or syncope
* able to read and speak English

Exclusion Criteria:

-CIED from other than Medtronic

Primary outcomes:
measure: Incidence of actionable events after use of readers in suspected TIA/stroke, heart failure and syncope
timeFrame: one day
Secondary outcomes:
measure: Average number of minutes from transmission to analysis
timeFrame: one day
Other outcomes:
measure: Incidence of non-EP trained staff rating CIED readers as very easy or easy
timeFrame: one year
Locations:
city: Naperville
country: United States
facility: Edward Hospital
state: Illinois
Study officials:
affiliation: Edward Hospital
name: Janet Gifford, MSN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05769946: A Study of Hemay005 in Adult With Atopic Dermatitis
Official title: A Phase II Study to Evaluate the Efficacy and Safety of Hemay005 Tablet in Adult With Moderate to Severe Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hemay005, Atopic Dermatitis
Lead sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2023-03-15
Enrollment: 79
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic dermatitis.


Eligibility criteria: Inclusion Criteria:

* Understand and voluntarily sign the informed consent form for this study;
* 18-75 years old (including boundary value) , gender is not limited;
* Ability to adhere to follow-up schedules and other program requirements;
* According to Hanifin \& Rajka diagnostic criteria of atopic dermatitis (AD) , the patients with AD history ≥6 months;
* At baseline, the severity of AD was moderate to severe: IGA score was 3 or more, and the area of involved skin lesion was 10% BSA or more;
* Participants were required to use contraception during the study period.

Exclusion Criteria:

* A medical history unsuitable for participation in a clinical study；
* Pregnant or lactating women；
* Allergic to the drug or its preparation；
* Patients who had undergone major surgery within 6 months before screening or who were scheduled for major surgery during the trial period；
* Participants who had participated in any drug or device clinical trial within the previous 3 months were screened；
* Vaccination with live or attenuated vaccines is planned for the duration of the trial；
* Any drugs is taking that may affect the effectiveness evaluation;
* Any clinically significant abnormality in 12-lead ECG at screening that was judged by the investigator as unsuitable for inclusion；
* When investgater believe that any condition could lead to unnecessary risks for patients participating in the study.

Primary outcomes:
measure: EASI-75
timeFrame: week 12
Secondary outcomes:
Other outcomes:
Locations:
city: Shijiazhuang
country: China
facility: First Hospital of Hebei Medical University
state: Hebei
Study officials:
References: